Abstract
Globally, chronic kidney disease (CKD) represents an important non-communicable disease with significant morbidity and mortality. An estimated 10% of the world’s population had CKD in 2015 with approximately 1.2 million deaths in 2017 ( 1, 2), and the burden is expected to rise at the rate of 6% per annum ( 3, 4). By 2030, more than 70% of patients suffering from end-stage kidney disease (ESKD) worldwide will be in low and lower middle income countries of the world including African countries ( 5). Significant disparities in the burden of CKD exist worldwide, where economically disadvantaged communities, notably those on the African continent and those of the African diaspora, continue to bear a disproportionate burden of the disease ( 2, 6). This disparity is fueled by a convergence of genetic and environmental risk factors ( 7, 8). A recent meta-analysis showed an overall prevalence of CKD of 15.8% in the general population in Africa, with up to 4.6% of adults having moderate to severe kidney dysfunction ( 9). In Africa, more than 80% of the continental burden of CKD is in sub-Saharan Africa (SSA), with the highest prevalence in West Africa ( 8). The burden of CKD among African Americans, who share substantial genetic ancestry with West Africans ( 10), is similarly high; African Americans represent 13% of the USA population, but account for 35% of the patients on dialysis ( 11).
Funding Information
  • Frederick National Laboratory for Cancer Research (HHSN261200800001E)
  • Intramural Research Program
  • National Institutes of Health
  • Frederick National Laboratory
  • Center for Cancer Research
  • South African National Research Foundation
  • Department of Health and Human Services